ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Citius Pharmaceuticals Inc

Citius Pharmaceuticals Inc (CTXR)

0.8522
0.0604
(7.63%)
At close: July 22 4:00PM
0.8393
-0.0129
( -1.51% )
After Hours: 7:33PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.8393
Bid
0.8393
Ask
0.8674
Volume
2,043,299
0.7705 Day's Range 0.8699
0.48 52 Week Range 1.19
Market Cap
Previous Close
0.7918
Open
0.801
Last Trade
25
@
0.8674
Last Trade Time
Financial Volume
$ 1,688,702
VWAP
0.826459
Average Volume (3m)
1,967,899
Shares Outstanding
180,673,355
Dividend Yield
-
PE Ratio
-4.61
Earnings Per Share (EPS)
-0.19
Revenue
-
Net Profit
-33.69M

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals, Inc. is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patient... Citius Pharmaceuticals, Inc. is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Carson City, Nevada, USA
Founded
1970
Citius Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CTXR. The last closing price for Citius Pharmaceuticals was $0.79. Over the last year, Citius Pharmaceuticals shares have traded in a share price range of $ 0.48 to $ 1.19.

Citius Pharmaceuticals currently has 180,673,355 shares outstanding. The market capitalization of Citius Pharmaceuticals is $143.06 million. Citius Pharmaceuticals has a price to earnings ratio (PE ratio) of -4.61.

CTXR Latest News

Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates

Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates PR Newswire CRANFORD, N.J., July 10, 2024 Multiple catalysts for potentially transformative assets in second half of...

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution PR Newswire CRANFORD, N.J., May 29, 2024 Management call scheduled...

Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution PR Newswire CRANFORD, N.J., May 21, 2024 Trial achieves statistically...

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update PR Newswire CRANFORD, N.J., May 14, 2024 Mino-Lok data analysis on track with...

Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences

Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences PR Newswire CRANFORD, N.J., May 10, 2024 CRANFORD, N.J., May 10, 2024 /PRNewswire/ -- Citius...

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering PR Newswire CRANFORD, N.J., April 30, 2024 CRANFORD, N.J., April 30, 2024 /PRNewswire/ -- Citius Pharmaceuticals...

Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

Citius Pharmaceuticals Announces $15 Million Registered Direct Offering PR Newswire CRANFORD, N.J., April 26, 2024 CRANFORD, N.J., April 26, 2024 /PRNewswire/ --Β Citius Pharmaceuticals Inc...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.107314.65846994540.7320.8940.726524650240.81324413CS
40.220335.58966074310.6190.8940.4824444430.70047156CS
120.164224.32232261890.67510.950.4819678990.69290878CS
260.119316.56944444440.721.070.4813663860.72070881CS
52-0.3507-29.47058823531.191.190.4810708780.76825392CS
156-1.2294-59.42862667382.06872.350.4813205521.30240997CS
260-0.2007-19.29807692311.044.560.424478441.80254715CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
157.94M
CMAXCareMax Inc
$ 5.19
(228.48%)
102.61M
NUKKNukkleus Inc
$ 0.499
(55.94%)
26.19M
SNOASonoma Pharmaceuticals Inc
$ 0.423
(37.34%)
4.87M
ONDSOndas Holdings Inc
$ 1.1297
(34.06%)
2.19M
LGCBLinkage Global Inc
$ 3.6601
(-29.82%)
168k
CGBSCrown LNG Holdings Ltd
$ 0.9997
(-29.10%)
3.38M
SPECSpectaire Holdings Inc
$ 0.3962
(-24.53%)
1.87M
GSUNGolden Sun Health Technology Group Ltd
$ 5.13
(-23.66%)
158.58k
PSNLPersonalis Inc
$ 2.9808
(-22.58%)
3.1M
NVDANVIDIA Corporation
$ 123.54
(4.76%)
238.8M
SQQQProShares UltraPro Short QQQ
$ 8.09
(-4.37%)
183.24M
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
157.94M
SERVServe Robotics Inc
$ 8.73
(15.63%)
151.44M
NCPLNetcapital Inc
$ 0.1118
(7.50%)
124.21M

CTXR Discussion

View Posts
2business 2business 7 hours ago
Today..Since..,multi$'price target-recentPR.news set..sudden-up.trend.as.if some.know
πŸ‘οΈ0
Monksdream Monksdream 3 weeks ago
CTXR new 52 week low
πŸ‘οΈ0
drkazmd65 drkazmd65 2 months ago
At last some good news on the catheter treatment,....

https://finance.yahoo.com/news/citius-pharmaceuticals-achieves-primary-secondary-110000306.html
πŸ‘οΈ0
ironman17 ironman17 4 months ago
https://www.sec.gov/Archives/edgar/data/1506251/000121390024022184/ea0201715-8k_citius.htm
πŸ‘οΈ0
Edward Edward 5 months ago
This was released on 2/14/2024, and the BLA was filed on 2/13/2024 with the FDA.

So if CTXR is correct CTXR should receive an answer within the next 2 weeks.

As of now, the 9:16am Pre market is looking good. Just have to wait and see if the normal trading hours follow through.

"FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act (PDUFA) date is expected within 30 days of resubmission."

https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Resubmits-the-Biologics-License-Application-of-LYMPHIR-Denileukin-Diftitox-for-the-Treatment-of-Adults-with-Relapsed-or-Refractory-Cutaneous-T-Cell-Lymphoma/default.aspx
πŸ‘οΈ0
Edward Edward 5 months ago
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
02/14/2024

FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act (PDUFA) date is expected within 30 days of resubmission

Link:
https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Resubmits-the-Biologics-License-Application-of-LYMPHIR-Denileukin-Diftitox-for-the-Treatment-of-Adults-with-Relapsed-or-Refractory-Cutaneous-T-Cell-Lymphoma/default.aspx
πŸ‘οΈ0
Edward Edward 6 months ago
Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
January 23, 2024

"This is a pivotal time for Citius as it prepares to transition from a clinical-stage company to a commercial organization"

https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Announces-Nomination-of-Pharmaceutical-Executive-Robert-J.-Smith-to-its-Board-of-Directors/default.aspx
πŸ‘οΈ0
mick mick 7 months ago
https://www.otcmarkets.com/stock/CTXR
πŸ‘οΈ0
Edward Edward 8 months ago
The shareholders will receive shares in the new company(see below).



"As previously announced, the Company is in the process of formulating a plan of distribution of a portion of the shares of Citius Oncology to its shareholders."


The wording is in the paragraph labeled(see link below) :

"CITIUS PHARMA AND TENX COMMENTS"

LINK:
citiuspharma.com/investors/...


Also, if CTXR owns 90% of the stock of the new company means they will pick up an unrealized gain if the price of the new company goes up since CTXR will carry the 90% as an investment and adjust the value to reflect the price also benefiting the stock price of CTXR and the stockholders will benefit also.

It's a win win.
πŸ‘οΈ0
Tacostocks Tacostocks 8 months ago
So basically if they make a spinoff company, it hurts CTXR investors big time because they wont see the benefit.
πŸ‘οΈ0
mick mick 9 months ago
https://www.otcmarkets.com/stock/CTXR
πŸ‘οΈ0
Edward Edward 9 months ago
Notice they said that the agreement had to be ratified by TenX but they didn't say anything about the CTXR investors having to vote on this. How could that be?

I am guessing the reason CTXR shareholders do not have to approve it is because CTXR is the only shareholder of the spin off company and the Board approved it: ( see below).

"the approval and adoption of the Merger Agreement and the transactions contemplated
thereby by the requisite vote of TenX’s shareholders (the β€œParent Shareholder Approval”) and the requisite approval of Citius Pharma, as SpinCo’s sole shareholder."
πŸ‘οΈ0
Doktornolittle Doktornolittle 9 months ago
Wow! What just happened? I think CTXR just bought itself for $750M. Given that it had only a $107M market cap, I think that is a pretty neat trick. Actually, it bought 90% of itself for $675M. What happened to the other 10%. Is this just a 10% dilution, or is this a 10% dilution where somebody gets skewered by a factor of (750/107 )/.9 = 7.8X. Now who would that be that would get skewered (if anyone)? CTXR is held; 7.8% by Insiders, 10.7% by Institutions, so I assume about 81.5% by Retail Investors. Must be the Institutional Investors and Insiders that are getting skewered if anyone... right? That is how this works, right? SPAC's are used by non-public companies that want to go public. This time it is a public company changing it's name. New use of an SPAC? Changing it's name and probably f%$&g you in the a%##. Deep down you can feel it, can't you? Notice they said that the agreement had to be ratified by TenX but they didn't say anything about the CTXR investors having to vote on this. How could that be? Ouch! Deeper! Cut that out! You should have known that something was fishy when the 100% efficacious Mino-Lok trial that should have ended a very long time ago went silent for so long. You have to wonder if the BLA submission issues were deliberate to tank the price and give time to set this (skewering?) up. As a wealthy manager once said to me after I invented something valuable for the company and then asked for a promotion, "You (retail investors) are used to not having any money. You don't need money". They on the other hand are very very rich, so they need your money more than you need it. It's all good.
πŸ‘οΈ0
mick mick 10 months ago
https://www.otcmarkets.com/stock/CTXR
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
CTXR new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
CTXR new 52 week low
πŸ‘οΈ0
mick mick 11 months ago
CTXR
Citius Pharmaceuticals Inc
0.955
-0.0414 (-4.15%)
Volume: 1,010,947
Day Range: 0.9384 - 1.00
Last Trade Time: 7:48:52 PM EDT
πŸ‘οΈ0
island man island man 1 year ago
Wow still alive
πŸ‘οΈ0
mick mick 1 year ago
CTXR Latest News Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes 06/26/2023 08:30:00 AM
Current Report Filing (8-k) 06/20/2023 04:06:30 PM
πŸ‘οΈ0
mick mick 1 year ago
$CTXR Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids 06/20/2023 08:30:00 AM
πŸ‘οΈ0
mick mick 1 year ago
$CTXR Citius Pharmaceuticals to Participate in Maxim Group's Virtual Healthcare Conference on June 21, 2023 06/13/2023 08:30:00 AM
πŸ‘οΈ0
mick mick 1 year ago
$CTXR Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update 05/12/2023 04:30:00 PM
πŸ‘οΈ0
mick mick 1 year ago
CTXR
Citius Pharmaceuticals Inc
1.17
-0.04 (-3.31%)
Volume: 627,282
Day Range: 1.18 - 1.24
Last Trade Time: 7:50:58 PM EDT
πŸ‘οΈ0
jrlsss jrlsss 1 year ago
Thank you. That explains it. Have my fingers crossed for a positive summer. I'm retiring next Friday, and it would be a nice safety net.
:)
πŸ‘οΈ0
Edward Edward 1 year ago
That was shares that were bought for the inclusion in the Russell index that was effective after the close today.

It was expected.

Today is the 4th Friday.

Every year on the fourth Friday of June, the Russell 1000, Russell 2000, Russell 3000 and other Russell indexes are reconstituted. FTSE Russell gives investors a heads up about what moves they should expect.
πŸ‘οΈ0
jrlsss jrlsss 1 year ago
What's up with the $10+ million share purchase at close?
πŸ‘οΈ0
drkazmd65 drkazmd65 1 year ago
Well - they have said that was their goal, and that it was 'supposed' to happen sometime during 2023. It would appear that things are moving forward.
πŸ‘οΈ0
Edward Edward 1 year ago
New spinoff company??

https://www.bizapedia.com/nj/citius-oncology-inc.html
πŸ‘οΈ0
Jayzp Jayzp 1 year ago
Ther Vs ctxr

Ther good news on cancer csn jump back to 52 week high

https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html
πŸ‘οΈ0
dtgsanjose dtgsanjose 1 year ago
best guess is that a large holder sold a chunk a couple of days ago, driving price down after a moderate run, and now a good number of folks are getting on board, seeing potential success coming a bit closer.
πŸ‘οΈ0
drkazmd65 drkazmd65 1 year ago
Interesting trading day here today. I can't find any new news - so I am not sure what's driving things.
πŸ‘οΈ0
drkazmd65 drkazmd65 1 year ago
A bit of news - Citius extends gains on advancing efforts to spin off oncology asset

https://seekingalpha.com/news/3952716-citius-stock-gains-on-spin-off-plans-for-oncology-asset

Mar. 30, 2023 9:29 AM ET
Citius Pharmaceuticals, Inc. (CTXR)
RDY
By: Dulan Lokuwithana, SA News Editor

After a 7% rise in the previous session, Citius Pharma (NASDAQ:CTXR) shares continued to gain in the pre-market Thursday after the company highlighted progress on its previously announced plans to spin off oncology candidate I/ONTAK into a standalone publicly-traded entity.

In a press release on Thursday, Citius (CTXR) said that in connection with the transaction, it has selected Maxim Group LLC as the financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp.

Following the spinoff, Citius (CTXR) is expected to continue to trade on the Nasdaq under its current ticker CTXR.
I/ONTAK is a reformulation of the previously FDA-approved oncology treatment ONTAK which was available in the U.S. market from 1999 – 2014 but voluntarily withdrawn later.

Citius (CTXR) and Dr. Reddy's (RDY) have a licensing deal for I/ONTAK, which is currently under FDA review for persistent or rare blood cancer recurrent cutaneous T-cell lymphoma (CTXR), with a decision expected by Sept. 28, 2023.

Read: Seeking Alpha contributor Bret Jensen issued a Hold rating on CTXR, noting that the upcoming FDA decision on I/ONTAK is a binary event.
πŸ‘οΈ0
KJAX KJAX 1 year ago
Who cares about E7777???
πŸ‘οΈ0
drkazmd65 drkazmd65 1 year ago
Fairly evenhanded article on Seeking Alpha this morning - a good read.

https://seekingalpha.com/article/4583270-citius-pharmaceuticals-stock-balanced-risk-reward-near-term-catalysts
πŸ‘οΈ0
DTL DTL 1 year ago
Your son left money on the table! CTXR is gaining momentum! How low did he sell for? I've been a shareholder/investor for 2 1/2 years and holding some $.87/shares, some a bit higher. I wouldn't dare trade this or sell CTXR so quickly unless desperate for money. $6 - $8/share as soon as I/Ontak and Mino-Lok hit their next milestones later this year. Get back in before the FOMO begins.
👍️ 1
Foxwoods Man Foxwoods Man 1 year ago
Maybe I am missing something but CTXR closed at $1.19 on the 24th and is at $1.32 now.
πŸ‘οΈ0
longboarder7892 longboarder7892 1 year ago
I just spoke with my son and he told me that CTXR if falling apart after he sold all our shares the other day. Wow this kid is getting better with his timing and taking the big profits. He will be getting a huge bonus- CTXR is down 15% today not a bad exit with a huge profit. O happy lunar new yr pp lol red is not a good look lol
πŸ‘οΈ0
sfld sfld 2 years ago
$10 by July? ??
πŸ‘οΈ0
longboarder7892 longboarder7892 2 years ago
I see my son was right again on CTXR on the Jan effect play almost a double here Sold 50000 shares today but hes keeping all the call options in case it still moves higher. He has learned from the master- lol now he can pay for our vacation to Cabo
πŸ‘οΈ0
drkazmd65 drkazmd65 2 years ago
Looks like the presentation was received with enthusiasm - market is pretty happy with Citius today.
πŸ‘οΈ0
longtrailer longtrailer 2 years ago
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update
PRESS RELEASE PR Newswire
Dec. 22, 2022, 04:30 PM

https://markets.businessinsider.com/news/stocks/citius-pharmaceuticals-inc-reports-fiscal-full-year-2022-financial-results-and-provides-business-update-1031987951
πŸ‘οΈ0
drkazmd65 drkazmd65 2 years ago
2023 could develop into a very good year for this little pharma company.
πŸ‘οΈ0
Edward Edward 2 years ago
F/Y/I

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma


https://citiuspharma.com/investors/news-media/news/release-details/2022/Citius-Pharmaceuticals-Inc.-Announces-U.S.-Food-and-Drug-Administration-Acceptance-of-Biologics-License-Application-of-Denileukin-Diftitox-for-the-Treatment-of-Patients-with-Persistent-or-Recurrent-Cutaneous-T-Cell-Lymphoma/default.aspx
πŸ‘οΈ0
drkazmd65 drkazmd65 2 years ago
Gracias!
πŸ‘οΈ0
Edward Edward 2 years ago
https://charts.stocktwits-cdn.com/production/original_492347263.png

They did say the spinoff of I/ONTAK would go into '23. They hope to have the "mechanical" aspect completed by EOY ( see link above)
πŸ‘οΈ0
drkazmd65 drkazmd65 2 years ago
OK - it's been a month+ since I last posted here. Anybody heard of any updates on the spin-off company idea? As I recall - the company said something about trying to do that during the 2nd half of 2022. We're rapidly running out of 2022 according to the old reliable wall calendar.
πŸ‘οΈ0
Foxwoods Man Foxwoods Man 2 years ago
Exactly...
πŸ‘οΈ0
drkazmd65 drkazmd65 2 years ago
Surprisingly little positive movement after such a bit of good news today.
πŸ‘οΈ0
Alot403 Alot403 2 years ago
2 or 3. Below 10 Or -5 below. Something in that range I think.
πŸ‘οΈ0
unityriver unityriver 2 years ago
I have a question for anyone who might have knowledge and experience in the area of spin-offs. What might be considered a typical pro rata ratio for number of shares in the new company issued to shareholders vs. number of shares held with the parent company? Thanks in advance.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock